De Lastours V, LeGoff J, Brière J, Agbalika F, Boulet T, Lévy Y, Simon F, Aboulker J-P and Molina J-M. Lymphoma
and Epstein-Barr virus DNA in blood during interleukin-2 therapy in
antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119
trial. HIV Médecine (2013) Lien PubMed
Launay O, Surenaud M, Desaint C,
Ben Hamouda N, Pialoux G, Bonnet B, Poizot-Martin I, Gonzales G, Cuzin
L, Bourgault-Villada I, Lévy Y, Choppin J, Durier C. Long-term
CD4+ and CD8+ T-cell responses induced in HIV-uninfected volunteers
following intradermal or intramuscular administration of an
HIV-lipopeptide vaccine (ANRS VAC16).Vaccine 2013 Jul 11.
j.vaccine.2013.06.102. Lien PubMed
Silva EF, Charreau I, Gourmel B,
Mourah S, Kalidi I, Guillon B, De Castro N, Caron F, Braun J, Molina JM
and the ANRS 138 Easier study group. Decreases in Inflammatory
and Coagulation Biomarkers Levels in HIV-Infected Patients Switching
from Enfuvirtide to Raltegravir: ANRS 138 Substudy. J Infect Dis2013,
208 : 892-897. Lien PubMed
Richert L, Hue S, Hocini H,
Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier
C, Salmon D, Lelièvre JD, Chêne G, Thiébaut R, Lévy Y; ANRS Vaccine
Network/Vaccine Research Institute. Cytokine and gene
transcription profiles of immune responses elicited by HIV lipopeptide
vaccine in HIV-negative volunteers.AIDS. 2013 Jun 1;27(9):1421-31. Lien PubMed
Richert L, Thiebaut R; Biostatistics Bioinformatics Division of the ANRS Vaccine Research Institute.Is
the current use of 'positivity' thresholds meaningful for evaluating
HIV-vaccine immunogenicity endpoints? AIDS. 2013 May 15;27(8):1362-5.
Collaborators: Richert L, Durier C, Surenaud M, Targat B, Wiedemann A,
Hue S, Hocini H, Lacabaratz C, Legrand R, Thiébaut R.
Bunupuradah T, Duong T,
Compagnucci A, McMaster P, Bernardi S, Kanjanavanit S, Rampon O, Faye A,
Saïdi Y, Riault Y, De Rossi A, Klein N, Ananworanich J, Gibb D; PENTA
11 Extension Study Group. Outcomes after reinitiating
antiretroviral therapy in children randomized to planned treatment
interruptions.AIDS. 2013 Feb 20;27(4):579-89. Lien PubMed
Durier C, Desaint C, Lucht F,
Girard PM, Lévy Y, May T, Michelet C, Rami A, Roman F, Delfraissy JF,
Aboulker JP, Launay O; for the ANRS 151 study group and the REIVAC
network. Long-term immunogenicity of two doses of 2009 A/H1N1v
vaccine with and without AS03A adjuvant in HIV-1-infected adults AIDS.
2013 Jan 2;27(1):87-93.Lien PubMed
Harrison L, Ananworanich J,
Hamadache D, Compagnucci A, Penazzato M, Bunupuradah T, Mazza A, Ramos
JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A,
Forcat S, Riault Y, Lallemant M, Castro H, Gibb DM, Giaquinto C;
Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team.Adherence
to antiretroviral therapy and acceptability of planned treatment
interruptions in HIV-infected children: AIDSBehav. 2013
Jan;17(1):193-202. Lien PubMed